Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.4K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.4K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

962
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
962

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Ketogenic Diet: Three Decades Later.

Journal of child neurology·2026
Same author

Exploring Beneath the Wave Surface: EEGs in DEEs.

Neurology·2026
Same author

Challenges and opportunities for the use of telehealth in rare disease diagnosis, treatment, research, and education: key opinion leader interviews by the IRDiRC telehealth task force.

Therapeutic advances in rare disease·2026
Same author

Telehealth for rare disease care, research, and education across the globe: A review of the literature by the IRDiRC telehealth task force.

European journal of medical genetics·2024
Same author

Training Clinical Scientists: At All Career Stages.

Neurology·2024
Same author

Global health for rare diseases through primary care.

The Lancet. Global health·2024
Same journal

Neuropsychological profile in dravet syndrome: A systematic review.

Epilepsy & behavior : E&B·2026
Same journal

Validation of the Spanish version of the Epilepsy Anxiety Survey Instrument (EASI) and its brief version (brEASI) in Colombian patients with drug-resistant epilepsy.

Epilepsy & behavior : E&B·2026
Same journal

Associations of self-esteem in people with epilepsy.

Epilepsy & behavior : E&B·2026
Same journal

Living with Dravet syndrome: quality of life and caregiver burden among family caregivers in Europe. Results from the QoL4DRAVET study.

Epilepsy & behavior : E&B·2026
Same journal

Executive function in functional/dissociative seizures: screening using the frontal assessment battery.

Epilepsy & behavior : E&B·2026
Same journal

Efficacy of adjunctive Yoga Nidra in patients with functional dissociative seizures receiving structured psychoeducation (YOGA-FDS): a pilot randomised controlled trial.

Epilepsy & behavior : E&B·2026
See all related articles

Related Experiment Video

Updated: Feb 19, 2026

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.5K

d-Leucine: Evaluation in an epilepsy model.

Kylie Holden1, Adam L Hartman2

  • 1Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States.

Epilepsy & Behavior : E&B
|November 11, 2017
PubMed
Summary
This summary is machine-generated.

D-leucine did not prevent chronic seizures in mice, but showed some effect during dark cycles. Mice lacking the Tas1R2/R3 receptor had improved seizure resistance, suggesting a new therapeutic target for epilepsy.

Keywords:
EpilepsyKainic acidSleepTaste receptorsd-Amino acid

More Related Videos

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

3.2K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

12.1K

Related Experiment Videos

Last Updated: Feb 19, 2026

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
05:33

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

3.5K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

3.2K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

12.1K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Epilepsy affects many patients inadequately treated by current medications.
  • D-leucine showed promise against acute seizures, but its efficacy in chronic epilepsy was unknown.

Purpose of the Study:

  • To investigate d-leucine's effect on spontaneous recurrent seizures in a mouse model.
  • To determine if Tas1R2/R3 receptor knockout mice are protected against acute seizures.

Main Methods:

  • Mice with kainic acid-induced status epilepticus were treated with d-leucine and monitored via EEG.
  • Tas1R2/R3 knockout mice and controls were tested using the maximal electroshock threshold (MES-T) and 6-Hz seizure tests.

Main Results:

  • D-leucine treatment did not alter overall seizure frequency or days with seizures.
  • An exploratory analysis indicated fewer dark cycle seizures in d-leucine treated mice.
  • Tas1R2/R3 knockout mice exhibited higher seizure thresholds in the MES-T test.

Conclusions:

  • D-leucine was ineffective for chronic seizures post-status epilepticus but showed potential for studying circadian epilepsy patterns.
  • The Tas1R2/R3 receptor may represent a novel therapeutic target for seizure management.